In this Q&A, esteemed Dr Rhoda Alani discusses the epigenetic landscape of therapy resistant melanomas and elucidates how corin treatment impacts the reprogramming of melanoma cell phenotypes. The findings suggest a new treatment paradigm for melanoma which could also be relevant to targeted therapy resistance mechanisms for other cancer types.
List view / Grid view
Ellen Capon (Drug Target Review)
Many exciting developments are expected to take place in immunotherapy and oncology in the next few years. We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments,…
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
Using an advanced human heart organoid system, researchers found the contributing factors to the condition and possible therapeutic compounds.
In light of the International Day for Women and Girls in Science, we had the privilege of speaking to Dr Jane Kendrew, Director of Translational Oncology at Sygnature Discovery. With over 30 years of drug discovery experience, she shares many insights, including her inspiration to pursue a career in STEM,…
In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells’ overall potential in regenerative medicine.
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
In this Q&A, Dr Gerard Wong elucidates the inflammatory capacity of fragmented viral components from the perspective of supramolecular self-organisation.
Distinct macrophage signatures that align specifically with regeneration could offer novel therapies to enhance wound healing.
In this Q&A, Keith Murphy, CEO of Organovo, discusses how the shift from animal models to 3D human tissues can transform the preclinical space. Among his many insights, he details the limitations of animal models, how Organovo’s 3D human tissue models facilitate a deeper understanding of genetic expression within specific…
Morphine is a frequently used analgesic that activates the mu-opioid receptor (MOR), which has prominent side effects of tolerance. A monoclonal antibody (mAb) precisely targeting MOR, named as 3A5C7, was developed to treat morphine tolerance by enhancing morphine-induced MOR endocytosis via GRK2/β-arrestin2 pathway. In this Q&A session with Dr Jia-Jia…
Producing functional human ACE2 protein in mouse cells provides a new way to study the receptor used by the SARS-CoV-2 spike protein.
Scientists demonstrate how disrupting the Cx26 molecular complex in triple-negative breast cancer cells slowed tumour growth.
New data provides an explanation for why, in almost all neurodegenerative diseases, disease sets in as cells age.